EWM
AMLX icon

Evolution Wealth Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Evolution Wealth Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-165
Closed -$1.99K – 854
2025
Q4 		$1.99K Hold
165
– – ﹤0.01% 640
2025
Q3 		$2.24K Buy
+165
New +$1.55K ﹤0.01% 500

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Evolution Wealth Management's AMLX Position: Q1 2026 in Review

Evolution Wealth Management sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 165 shares — an estimated $1.99K sold.

Evolution Wealth Management first reported a position in AMLX in Q3 2025 and held it in 2 quarters. The position peaked at $2.24K in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Evolution Wealth Management reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Evolution Wealth Management sold 165 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $1.99K.
  • Evolution Wealth Management first reported a position in Amylyx Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Evolution Wealth Management's Amylyx Pharmaceuticals position peaked at $2.24K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Evolution Wealth Management's 13F filing for Q1 2026, filed 27 Apr 2026.